Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study

Area of Science:

• Psychiatry and Pharmacology
• Clinical Neuroscience

Background:

• Schizophrenia is a complex psychiatric disorder often managed with antipsychotic medications.
• Haloperidol (HL) is a typical antipsychotic, but its efficacy and side effect profile can be limiting.
• Clonazepam (CLN), a benzodiazepine, has shown potential in managing certain psychiatric symptoms.

Purpose of the Study:

• To investigate the efficacy and safety of combining clonazepam (CLN) with haloperidol (HL) in schizophrenia patients.
• To compare the combination therapy against haloperidol (HL) monotherapy in a double-blind setting.

Main Methods:

• A 4-week double-blind study involving 24 schizophrenic inpatients diagnosed via DSM III criteria.
• Participants were randomized to receive either haloperidol (HL) plus clonazepam (CLN) (Group 1) or haloperidol (HL) plus placebo (Group 2).
• Psychopathological symptoms and extrapyramidal side effects were assessed weekly using the Brief Psychiatric Rating Scale (BPRS) and Extrapyramidal Side Effect Scale (EPSE).

Main Results:

• While no significant differences in overall schizophrenic symptoms were found, Group 1 (HL + CLN) showed early significant BPRS amelioration compared to Group 2 (HL + placebo).
• The 'excitement' item on the BPRS improved significantly in Group 1 from week 2 onwards.
• Group 1 also exhibited significantly less severe extrapyramidal side effects (EPSE) compared to Group 2.

Conclusions:

• The combination of clonazepam (CLN) and haloperidol (HL) appears to be more effective than haloperidol (HL) alone for managing psychotic excitement in schizophrenia.
• This combination may also be beneficial in reducing the severity of extrapyramidal side effects associated with haloperidol treatment.
• Further research is warranted to explore the long-term benefits and optimal use of CLN in conjunction with HL for schizophrenia management.